List of Excipients in Branded Drug ALOGLIPTIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Padagis Israel Pharmaceuticals Ltd	ALOGLIPTIN	alogliptin	45802-087	ALCOHOL	2026-07-27
Padagis Israel Pharmaceuticals Ltd	ALOGLIPTIN	alogliptin	45802-087	BUTYL ALCOHOL	2026-07-27
Padagis Israel Pharmaceuticals Ltd	ALOGLIPTIN	alogliptin	45802-087	CELLULOSE, MICROCRYSTALLINE	2026-07-27

Alogliptin Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Alogliptin is an oral dipeptidyl peptidase-4 inhibitor marketed primarily as alogliptin benzoate. Its excipient opportunity is strongest in generic tablets, fixed-dose combinations, regional reformulations, and manufacturing-cost reduction rather than in new chemical-entity exclusivity. The product is suited to immediate-release oral solid dosage forms using conventional direct-compression or wet-granulation platforms.

The commercial case depends on four factors: reliable supply of alogliptin benzoate, bioequivalent tablet performance, low-cost excipient selection, and differentiation through fixed-dose combinations or patient-use features. FDA-approved products include Nesina, Kazano, and Oseni. The products are regulated under abbreviated new drug application or 505(b)(2)-type strategies depending on the proposed formulation and product scope.[1-4]

What is alogliptin and how is it formulated?

Alogliptin is a selective DPP-4 inhibitor used to improve glycemic control in adults with type 2 diabetes. The marketed active pharmaceutical ingredient is generally alogliptin benzoate, a crystalline salt selected for pharmaceutical development and solid-dose manufacture.

Nesina is an immediate-release tablet. The FDA label identifies a conventional excipient system that includes mannitol, microcrystalline cellulose, hydroxypropyl cellulose, crospovidone, magnesium stearate, and colorants in certain strengths.[1] The formulation indicates that alogliptin does not require a complex delivery system for oral absorption.

Alogliptin product portfolio

Product	Active ingredients	Dosage form	Original sponsor	Regulatory status
Nesina	Alogliptin benzoate	Immediate-release tablet	Takeda	FDA-approved
Kazano	Alogliptin benzoate and metformin hydrochloride	Immediate-release tablet	Takeda	FDA-approved
Oseni	Alogliptin benzoate and pioglitazone	Immediate-release tablet	Takeda	FDA-approved
Generic alogliptin products	Alogliptin benzoate	Immediate-release tablet	Multiple manufacturers and applicants by market	Subject to local approval

The principal excipient challenge in the combination products is not alogliptin alone. It is the need to accommodate the higher dose, compression behavior, hygroscopicity, dissolution requirements, and chemical compatibility of metformin or pioglitazone.[2-4]

What excipients are used in alogliptin tablets?

Alogliptin tablets use a relatively standard immediate-release excipient platform.

Excipient	Primary function	Strategic relevance
Mannitol	Diluent and bulking agent	Improves mouthfeel and supports low-dose drug distribution
Microcrystalline cellulose	Diluent and dry binder	Provides compactibility and tablet strength
Hydroxypropyl cellulose	Binder	Supports granule or tablet integrity
Crospovidone	Superdisintegrant	Promotes rapid tablet breakup
Magnesium stearate	Lubricant	Controls ejection force and tooling performance
Iron oxides or other colorants	Identification and dose differentiation	Supports product-line management

Alogliptin is a relatively low-dose active compared with metformin. Content uniformity therefore becomes a central manufacturing issue. The formulation must distribute the active evenly through the powder blend while avoiding over-lubrication, segregation, and delayed dissolution.

Why mannitol is commercially useful

Mannitol is attractive in alogliptin formulations because it offers good compactability in suitable grades, low hygroscopicity relative to several alternative polyols, and a neutral sensory profile. Direct-compression mannitol can support a simplified manufacturing process.

The main disadvantages are cost and potential sensitivity to particle-size distribution. A low-cost generic formulation may replace part or all of the mannitol with lactose, dibasic calcium phosphate, starch-based fillers, or a mannitol-cellulose blend. Each substitution requires comparative dissolution, stability, and bioequivalence assessment.

Why microcrystalline cellulose remains important

Microcrystalline cellulose provides dry-binding capacity and reduces the risk of weak tablets when the active is present at a low loading. It can also improve blend robustness when the formulation uses direct compression.

Its limitations include variability in flow, sensitivity to compression force, and possible interaction with high-moisture processing conditions. Co-processed cellulose systems can improve flow and compactibility but may increase material cost and regulatory documentation.

Disintegrant selection

Crospovidone is consistent with a rapid-release tablet strategy. Croscarmellose sodium and sodium starch glycolate are technically credible alternatives. The choice affects:

• Disintegration time
• Dissolution rate
• Tablet friability
• Sensitivity to compression force
• Performance after accelerated storage

For a generic product, a change from crospovidone to croscarmellose sodium is unlikely to create meaningful commercial differentiation by itself. It can, however, reduce cost or improve robustness if the original formulation has poor dissolution after high-force compression.

What excipient strategy is best for generic alogliptin?

The preferred strategy is a low-risk immediate-release formulation that uses compendial excipients with established regulatory histories.

Direct-compression strategy

A direct-compression formula can use:

• Alogliptin benzoate
• Mannitol or lactose-mannitol blend
• Microcrystalline cellulose
• Crospovidone or croscarmellose sodium
• Hydroxypropyl cellulose or copovidone where additional binding is required
• Magnesium stearate
• Colloidal silicon dioxide if flow improvement is needed

This approach reduces water exposure, shortens processing time, and avoids drying-related variability. It is most attractive where the powder blend has acceptable flow and content uniformity.

Wet-granulation strategy

Wet granulation may be preferred when the active or excipient blend has poor flow, segregation risk, or inadequate tablet strength. Hydroxypropyl cellulose, povidone, or copovidone can be used as binders.

The disadvantages are greater process complexity, higher energy use, and potential moisture-related stability concerns. Wet granulation also creates a larger process-development burden for a low-margin generic product.

Granulation and coating opportunities

Alogliptin tablets can be differentiated through:

• Film coatings that improve swallowability
• Color-coded strengths
• Low-dust manufacturing
• Reduced tablet size
• Modified packaging for humidity control
• Scored tablets where permitted by product design
• Pediatric or geriatric-friendly dosage concepts, subject to regulatory justification

A conventional film coat based on hypromellose, polyethylene glycol, titanium dioxide, and approved colorants is unlikely to create strong patent protection. Its value is operational and commercial: product identification, handling, and patient acceptability.

What formulations are protected by alogliptin patents?

The principal historic patent value was associated with alogliptin as a chemical entity, its salts, pharmaceutical compositions, and therapeutic use. Product-specific patents may also cover fixed-dose combinations or particular dosage forms.

The relevant protection categories include:

Protection category	Relevance to alogliptin
Composition-of-matter patents	Covered alogliptin and related DPP-4 inhibitor structures
Salt and crystal-form patents	May cover alogliptin benzoate or solid-state forms
Pharmaceutical-composition patents	May cover tablets, excipient systems, or dosage ranges
Method-of-use patents	May cover treatment of type 2 diabetes and combinations
Combination-product patents	Relevant to alogliptin-metformin and alogliptin-pioglitazone
Manufacturing patents	May cover crystallization, purification, or API production

The FDA Orange Book remains the controlling source for current U.S. listed patents and regulatory exclusivities.[5] Because listings differ by NDA and can change through delisting, expiration, or litigation, the Orange Book status must be reviewed separately for Nesina, Kazano, and Oseni.

When does alogliptin lose exclusivity?

Alogliptin's original U.S. new-drug exclusivity and core patent protection are no longer the principal commercial barrier for most generic developers. The practical market barriers are now product approval, API quality, bioequivalence, manufacturing scale, and reimbursement access.

A generic applicant may still face risk from:

• Unexpired listed patents for a specific product
• Method-of-use patents
• Combination-product patents
• Patent-term adjustments or extensions
• Regulatory exclusivity attached to a particular indication
• Formulation or crystalline-form claims in specific jurisdictions

What is the Paragraph IV risk for alogliptin?

Paragraph IV risk depends on the specific reference listed drug and the patents listed against it. A generic applicant asserting that a listed patent is invalid, unenforceable, or not infringed can trigger litigation under the Hatch-Waxman framework.[6]

For alogliptin, the highest risk historically would have been associated with early generic filings against the active ingredient or branded combination products. Current risk is more likely to arise from product-specific patents, combination claims, or jurisdictional differences than from the original molecule patent alone.

What generic launch opportunities exist for alogliptin?

The best launch opportunities are in markets where:

1. The reference product has lost effective exclusivity.
2. Alogliptin remains included in national treatment guidelines or reimbursement formularies.
3. Generic DPP-4 inhibitors have stable demand.
4. Local manufacturing or tender access creates a price advantage.
5. Fixed-dose combinations are underdeveloped.

Alogliptin competes with sitagliptin, linagliptin, saxagliptin, vildagliptin, and other DPP-4 inhibitors. Sitagliptin has historically had the largest global commercial footprint in the class, while linagliptin has differentiated itself through dosing convenience in renal impairment. Alogliptin's competitive position is stronger where pricing, combination availability, or local formulary rules outweigh brand recognition.

Commercial opportunity by product type

Opportunity	Commercial attractiveness	Main barrier
Plain alogliptin tablet	Moderate	Generic price erosion
Alogliptin-metformin combination	Moderate to high in selected markets	High-dose formulation and bioequivalence
Alogliptin-pioglitazone combination	Selective	Smaller clinical demand and safety perceptions surrounding pioglitazone
Regional blister-pack products	Moderate	Packaging and local reimbursement requirements
Hospital or tender supply	Moderate	Price competition and supply qualification
Novel modified-release product	Low to moderate	Clinical and regulatory burden
Pediatric formulation	Uncertain	Limited indication and clinical-development requirements
Co-pack or adherence product	Selective	Limited patent durability and reimbursement uncertainty

How does alogliptin compare with competing DPP-4 inhibitors?

Drug	Typical differentiation	Excipient strategy implications
Alogliptin	Oral once-daily DPP-4 inhibition	Conventional immediate-release tablet
Sitagliptin	Large established market and broad generic activity	Strong pressure on cost and supply
Linagliptin	Renal dosing convenience	Higher value in renal-impairment segments
Saxagliptin	Once-daily oral dosing	Combination and safety positioning affect demand
Vildagliptin	Strong presence in selected non-U.S. markets	Regional formulation and tender opportunities

Alogliptin does not require a technically complex excipient system to compete. Its weakness is commercial differentiation. A generic manufacturer therefore gains more from cost control, combination availability, reliable supply, and market access than from a novel excipient platform.

What manufacturing and intellectual-property barriers exist?

The main manufacturing barriers are practical rather than highly specialized.

API and solid-state control

Alogliptin benzoate requires control of:

• Identity and assay
• Residual solvents
• Related substances
• Particle-size distribution
• Polymorphic or crystalline form
• Water content
• Blend uniformity
• Stability under humidity and temperature stress

If a patent or regulatory filing claims a particular salt, polymorph, or manufacturing route, an alternative solid-state form may require additional characterization and regulatory justification.

Content uniformity

Low-dose alogliptin creates risk of segregation during blending, transfer, and compression. Particle-size matching between the API and major diluent can reduce this risk. Ordered mixing, geometric dilution, or a preblend can support uniformity.

Dissolution

The target is a rapid and reproducible immediate-release profile. Dissolution performance can be affected by:

• Lubricant concentration and mixing time
• Compression force
• Disintegrant level
• API particle size
• Granule density
• Film-coat weight
• Storage humidity

A formulation that matches assay and content uniformity but shows slower dissolution may create bioequivalence risk.

What is the FDA regulatory status of alogliptin products?

Nesina, Kazano, and Oseni were approved by FDA in 2013.[1-3] They are prescription products regulated as new drugs. Generic development generally proceeds through an ANDA referencing the applicable listed drug, subject to the patent certifications and exclusivity provisions in the Orange Book.[5-6]

A formulation that changes the active salt, release profile, dosage form, or indication may fall outside a straightforward ANDA strategy. A 505(b)(2) pathway may be relevant where the proposed product relies partly on FDA findings for a listed product but differs materially in formulation or route.[7]

What licensing deals and commercial arrangements matter?

The most relevant commercial arrangements involve:

• Alogliptin benzoate API supply
• Regional rights to alogliptin tablets
• Co-development of alogliptin-metformin combinations
• Authorized generic or branded-generic distribution
• Contract manufacturing for tablets and packaging
• Local tender and government procurement rights

The licensing value of a plain alogliptin tablet is limited by generic competition. Combination products and markets with lower generic penetration offer greater potential value. API manufacturers with reliable crystallization, impurity control, and regulatory documentation can capture value even when finished-dose margins decline.

What is the likely revenue exposure from alogliptin?

Branded revenue exposure is likely concentrated in the remaining markets where Takeda or its commercial partners retain reimbursement access. Generic revenue exposure is more dependent on unit volume, tender wins, and manufacturing cost than on premium pricing.

A manufacturer should evaluate:

• Annual prescription volume by country
• Reimbursement price and reference pricing
• Number of approved generic competitors
• Local API registration requirements
• Fixed-dose combination demand
• Supply reliability of alogliptin benzoate
• Potential substitution by sitagliptin or linagliptin

The most defensible commercial position is a low-cost, quality-consistent product with multiple strengths and at least one high-volume fixed-dose combination.

Key Takeaways

• Alogliptin is well suited to conventional immediate-release tablet manufacturing.
• The reference excipient platform uses mannitol, microcrystalline cellulose, hydroxypropyl cellulose, crospovidone, and magnesium stearate.
• Generic developers can reduce cost through direct compression, excipient substitution, and optimized particle-size control.
• Fixed-dose combinations with metformin offer the strongest formulation opportunity.
• Core molecule exclusivity is no longer the main barrier in most markets, but product-specific patents and Orange Book listings must be reviewed by NDA.
• Paragraph IV exposure depends on the specific reference product and any remaining listed patents.
• Biosimilar risk is not relevant because alogliptin is a synthetic small molecule, not a biologic.
• Manufacturing quality, API supply, bioequivalence, and reimbursement access are more important than novel excipient claims.
• Commercial differentiation is stronger through combination products and regional market access than through a new coating or diluent system.

FAQs

Is alogliptin a biologic or a small-molecule drug?

Alogliptin is a synthetic small-molecule DPP-4 inhibitor. Biosimilar regulation does not apply. Generic applicants use small-molecule pathways such as an ANDA where the product meets applicable requirements.

Can lactose replace mannitol in alogliptin tablets?

Lactose can be evaluated as a diluent, but replacement requires formulation development and comparative dissolution, stability, content-uniformity, and bioequivalence assessment. The change may also affect moisture sensitivity and tablet hardness.

Which alogliptin product offers the strongest generic opportunity?

Alogliptin-metformin is generally the most commercially relevant combination opportunity because metformin has large patient volume. The formulation is more demanding because of the high metformin load and the need to control tablet size, dissolution, and content uniformity.

Does alogliptin require an enteric coating?

No. Approved alogliptin products are immediate-release oral tablets and do not require enteric protection for their intended administration.

Can a novel alogliptin excipient formulation obtain patent protection?

Potentially, but routine substitution of common diluents or disintegrants is unlikely to produce strong patent value. A defensible claim would generally require a non-obvious formulation, measurable performance advantage, or clinically meaningful delivery benefit.

References

1. U.S. Food and Drug Administration. (2013). Nesina (alogliptin benzoate) prescribing information.
2. U.S. Food and Drug Administration. (2013). Kazano (alogliptin benzoate and metformin hydrochloride) prescribing information.
3. U.S. Food and Drug Administration. (2013). Oseni (alogliptin benzoate and pioglitazone hydrochloride) prescribing information.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
6. 21 U.S.C. § 355(j). Abbreviated applications for new drugs.
7. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).